

## **InterAx Biotech AG appoints Andrew Roberts as Chief Executive Officer**

***Seasoned drug development and portfolio strategy leader to fully leverage InterAx's platform toward a high-value internal pipeline***

***Zurich, Switzerland – October 7<sup>th</sup> 2025 - InterAx Biotech AG announces the appointment of Andrew Roberts as Chief Executive Officer. He will accelerate the company's transition from a drug discovery technology pioneer into a developer of safer and more efficacious GPCR-class drugs while maturing its transformative drug discovery platform across multiple therapeutic areas. Roberts will guide InterAx's next phase of growth: maximizing the capabilities of its technology platform to generate a robust portfolio of drug candidates with an initial focus on metabolic diseases. Key priorities include fundraising, advancing lead programs towards clinical development and strategically expanding the pipeline.***

"Andrew's experience building complex development portfolios and generating significant value for shareholders—and his immediate rapport with our team—make him the right leader for this pivotal stage," said Dr. Jens Gobrecht, Chair of the Board. "Under his leadership, InterAx will sharpen strategy, drive to clinical proof-of-concept, and build durable value through rigorous execution."

Roberts brings 20+ years of end-to-end biopharmaceutical R&D and portfolio leadership across Big Pharma and Biotech organizations such as Novartis, Sandoz and Biogen Idec. He has served as Chief Portfolio Officer at Alvotech, where he played a significant role in building a research and development portfolio and growing the organization, capabilities and partnerships towards a successful IPO. He is also a Partner at Thaxton Philip Consulting, advising pharmaceutical companies and biotech, investors, VC and PE firms and law firms on portfolio strategy, governance, and drug development activities.

Roberts has deep experience in drug development across a variety of therapeutic areas, indications and phases, having worked on over 40 development programs from translational medicine through to post-marketing studies. His contributions have led to the approval of over 15 new products. Roberts holds an Executive MBA from INSEAD and advanced degrees in nutrition and biological sciences from Louisiana State University.

"I'm excited to join InterAx at this inflection point," said Andrew Roberts. "Our mission is to maximize the full power of our platform to create a high-value portfolio of drug candidates—initially in the metabolic space—and to advance those programs efficiently to the clinic."

### **InterAx Biotech AG**

InterAx is an AI-driven drug discovery company with a first-in-class platform that uncovers how drugs work at a deeper physiological level—enabling better drug design and a higher success rate in development. Backed by a world-class team of scientists and industry leaders, InterAx is advancing wholly owned oral candidates for the \$100B+ metabolic disease market. These weight-loss and diabetes therapies aim to match high efficacy with fewer side effects, offering a more accessible, cost-effective alternative to current injectables. With a scalable pipeline and precision biology expertise, InterAx is poised for lasting clinical and commercial impact.